Jim Mustian and Joshua Goodman broke the story of how the U.S. Drug Enforcement Administration’s second-in-command quietly stepped down after they had reported that he had previously done extensive consulting work for pharmaceutical companies, including the drug maker that became the face of the opioid crisis, Purdue Pharma.
The recent departure of Principal Deputy Administrator Louis Milione was just the latest fallout from Goodman and Mustian’s months of reporting about turmoil at the top of the DEA at a time when American overdose deaths have soared to more than 110,000 a year.